Advertisement
Advertisement

VRTX

VRTX logo

Vertex Pharmaceuticals Inc

480.33
USD
+3.90
+0.81%
Feb 21, 16:00 UTC -5
Closed
exchange

After-Market

486

+5.67
+1.18%

Vertex Pharmaceuticals Inc Profile

About

Vertex Pharmaceuticals Incorporated is focused on the discovery, development, and commercialization of small molecule drugs targeting serious diseases. The company's main area of focus is cystic fibrosis. The company's lead marketed products are Trikafta, Symdeko/Symkevi, Orkambi and Kalydeco, which are collectively approved to treat the people with CF in North America, Europe and Australia. Trikafta, Vertex's triple combination regimen, was approved by the FDA for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency and muscular dystrophies. Pimodivir/VX-787, for the treatment of influenza, was out-licensed to Janssen while oncology candidates VX-970, VX-984 and VX-803 were divested to Merck KGaA.

Info & Links

CEO

Reshma Kewalramani

Headquarters

50 NORTHERN AVENUE
BOSTON, MA 02210, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.vrtx.com

Auditor

Ernst & Young LLP

Share holders

101

Employees

6,100

Vertex Pharmaceuticals Inc Statistics

Valuation Measures

Market Capitalization2

124.80B

Enterprise Value

120.34B

Enterprise Value/EBITDA(ttm)

-4.68K

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

11.19

Price to Book(mrq)

7.54

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

86.13%

Operating Margin(ttm)

-3.00%

Profit Margin(ttm)

-6.47%

Return on Equity(ttm)

-2.02%

Return on Invested Capital(ttm)

-5.78%

Return on Assets(ttm)

-1.49%

Income Statement

Revenue(ttm)

11.02B

Revenue Per Share(ttm)

42.91

Gross Profit(ttm)

9.49B

EBITDA(ttm)3

-25.70M

Net Income Available to Common(ttm)

-535.60M

Diluted EPS(ttm)

-2.20

Share Statistics

Beta (5Y Monthly)

0.41

52-Week Change

14.47%

S&P 500 52-Week Change

18.16%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

256.79M

Dividend Yield

0.00%

Float4

256.28M

% Held by Insiders

0.20%

% Held by Institutions

90.96%

Balance Sheet

Total Cash(mrq)

6.12B

Total Cash Per Share(mrq)

23.82

Total Debt(mrq)

112.80M

Total Debt/Equity(mrq)

0.69%

Current Ratio(mrq)

2.69%

Quick Ratio(mrq)

2.35%

Book Value Per Share(mrq)

63.87

Cash Flow

Operating Cash Flow Per Share(ytd)

-1.91

Free Cash Flow(ytd)

-790.30M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement